Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates

7Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Schizophrenia is a disorder characterized by cognitive impairment and psychotic symptoms that fluctuate over time and can only be mitigated with the chronic administration of antipsychotics. Here, we propose biodegradable microPlates made of PLGA for the sustained release of risperidone over several weeks. Two microPlate configurations – short: 20 × 20 × 10 μm; tall: 20 × 20 × 20 μm – are engineered and compared to conventional ~ 10 μm PLGA microspheres in terms of risperidone loading and release. Tall microPlates realize the slowest release documenting a 35% risperidone delivery at 100 days with a residual rate of 30 ng/ml. Short microPlates and microspheres present similar release profiles with over 50% of the loaded risperidone delivered within the first 40 days. Then, the therapeutic efficacy of one single intraperitoneal injection of risperidone microPlates is compared to the daily administration of free risperidone in heterozygous knockout mice for dysbindin-1, a clinically relevant mouse model of cognitive and psychiatric liability. In temporal order object recognition tasks, mice treated with risperidone microPlates outperform those receiving free risperidone up to 2, 4, 8, and 12 weeks of observation. This suggests that the sustained release of antipsychotics from one-time microPlate deposition can rescue cognitive impairment in dysbindin mice for up to several weeks. Overall, these results demonstrate that risperidone-loaded microPlates are a promising platform for improving cognitive symptoms associated to schizophrenia. Moreover, the long-term efficacy with one single administration could be of clinical relevance in terms of patient’s compliance and adherence to the treatment regimen. Graphical abstract: Single injection of long-acting risperidone-loaded µPL ameliorates the dysbindin-induced deficit in a clinically relevant mouse model of cognitive and psychiatric liability for up to 12 weeks [Figure not available: see fulltext.]

References Powered by Scopus

Schizophrenia - An Overview

780Citations
N/AReaders
Get full text

Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence

741Citations
N/AReaders
Get full text

Genetic variation in the 6p22.3 Gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia

729Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Current and future directions of drug delivery for the treatment of mental illnesses

10Citations
N/AReaders
Get full text

Evaluating Non-Conventional Chitosan Sources for Controlled Release of Risperidone

9Citations
N/AReaders
Get full text

Tackling myelin deficits in neurodevelopmental disorders using drug delivery systems

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bellotti, E., Contarini, G., Geraci, F., Torrisi, S. A., Piazza, C., Drago, F., … Decuzzi, P. (2022). Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates. Drug Delivery and Translational Research, 12(8), 1829–1842. https://doi.org/10.1007/s13346-021-01099-x

Readers over time

‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

Professor / Associate Prof. 1

33%

Lecturer / Post doc 1

33%

Researcher 1

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Chemistry 2

40%

Pharmacology, Toxicology and Pharmaceut... 1

20%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0